Pueraria Menopause Randomized Trial: What the Evidence Says

Quick Answer

Pueraria Menopause Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Despite its burgeoning commercial presence in the global nutraceutical and cosmetic markets, the scientific evidence supportingremains fragmented. [Zeng Haiqin (2026); evidence level 3]
• It is estimated that a significant proportion of postmenopausal women, ranging from 36 % to almost 90 %, experience symptoms associated with vulvovaginal atrophy (VVA). [Naderi-afshar Elahe (2026); evidence level 4]
• This lack of reporting can result in underdiagnoses and under treatment of the condition, despite the significant impact that VVA symptoms can have on daily activities, sexual function, interpersonal relationships, and overall quality of life for postmenopausal women. [Naderi-afshar Elahe (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For pueraria menopause randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Zeng Haiqin (2026). Pueraria mirifica : a critical review of the ethnobotany, phytochemistry, pharmacology and challenges in standardization and safety. DOI: 10.3389/fphar.2026.1820644. PMCID: PMC13279689. PMID: 42328653. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13279689/
• Naderi-afshar Elahe (2026). Effect of Persian traditional medicine based herbal vaginal gel in vaginal atrophy. DOI: 10.1016/j.jaim.2025.101193. PMCID: PMC13068819. PMID: 41930850. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13068819/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.